Tamoxifen and aminoglutethimide in the management of patients with advanced endometrial carcinoma not responsive to medroxyprogesterone.
Eleven patients with advanced endometrial carcinoma not responsive to medroxyprogesterone were entered into a trial of therapy with tamoxifen, aminoglutethimide or both in combination. Two patients had a complete response, 1 to aminoglutethimide and 1 to tamoxifen. One patient who initially had a partial response to tamoxifen but then relapsed, had a partial response to aminoglutethimide. Two patients had stable disease for 8 and 6 months on aminoglutethimide, and 1 patient who initially showed no response to tamoxifen has had stable disease for 14 months since addition of aminoglutethimide to therapy. The relative lack of toxicity of these drugs make their use attractive in the management of such patients.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000368:Aged; D000616:Aminoglutethimide / Q000009:adverse effects / Q000627:therapeutic use*; D004351:Drug Resistance; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008525:Medroxyprogesterone / Q000627:therapeutic use*; D008875:Middle Aged; D013629:Tamoxifen / Q000009:adverse effects / Q000627:therapeutic use*; D014594:Uterine Neoplasms / Q000188:drug therapy*
D013629:Tamoxifen; D000616:Aminoglutethimide; D008525:Medroxyprogesterone